{"protocolSection": {"identificationModule": {"nctId": "NCT00742508", "orgStudyIdInfo": {"id": "CRV110734"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure", "officialTitle": "A Study to Evaluate the Safety and Tolerability of SK&F-105517-D in Patients With Chronic Heart Failure- An Open-label Study to Evaluate the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SK&F-105517-D in Patients With Chronic Heart Failure (Phase I/II Study)"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-08-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2009-08-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-08-26", "studyFirstSubmitQcDate": "2008-08-26", "studyFirstPostDateStruct": {"date": "2008-08-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-17", "resultsFirstSubmitQcDate": "2010-07-23", "resultsFirstPostDateStruct": {"date": "2010-08-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-06-27", "lastUpdatePostDateStruct": {"date": "2017-08-02", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to evaluate the safety and tolerability of SK\\&F-105517-D in japanese patients with chronic heart failure."}, "conditionsModule": {"conditions": ["Heart Failure, Congestive"], "keywords": ["carvedilol phosphate", "\u00df-blocker", "SK&F-105517-D", "Chronic heart failure(CHF)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 41, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "SK&F-105517-D group", "type": "EXPERIMENTAL", "description": "SK\\&F-105517-D 10-80 mg/day", "interventionNames": ["Drug: SK&F-105517-D 10 mg capsule", "Drug: SK&F-105517-D 20 mg capsule", "Drug: SK&F-105517-D 40 mg capsule"]}, {"label": "Carvedilol-IR group", "type": "OTHER", "description": "Carvedilol-IR 5-20 mg/day", "interventionNames": ["Drug: Carvedilol-immediate release (IR) 2.5 mg tablet", "Drug: Carvedilol-IR 10 mg tablet"]}], "interventions": [{"type": "DRUG", "name": "SK&F-105517-D 10 mg capsule", "description": "1 capsule once a day", "armGroupLabels": ["SK&F-105517-D group"], "otherNames": ["carvedilol phosphate"]}, {"type": "DRUG", "name": "Carvedilol-immediate release (IR) 2.5 mg tablet", "description": "1 or 2 tablet(s) twice a day", "armGroupLabels": ["Carvedilol-IR group"]}, {"type": "DRUG", "name": "SK&F-105517-D 20 mg capsule", "description": "1 capsule once a day", "armGroupLabels": ["SK&F-105517-D group"], "otherNames": ["carvedilol phosphate"]}, {"type": "DRUG", "name": "SK&F-105517-D 40 mg capsule", "description": "1 or 2 capsule(s) once a day", "armGroupLabels": ["SK&F-105517-D group"], "otherNames": ["carvedilol phosphate"]}, {"type": "DRUG", "name": "Carvedilol-IR 10 mg tablet", "description": "1 tablet twice a day", "armGroupLabels": ["Carvedilol-IR group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Events by Severity From Week 0 Through Week 8 (CRV-IR) or Week 14 (SK&F-105517-D)", "description": "Drug-related adverse events (AEs) were defined as AEs that were judged to have a relationship with the investigational product by the investigator (or subinvestigator) with the use of clinical judgment and the Clinical Investigator Brochure to determine the relationship. Refer to adverse event information for type and frequency of adverse events.", "timeFrame": "Treatment Period from Week 0 (Baseline) to Week 8 and 1-week Follow-up Period (Week 9) for CRV-IR; Treatment Period from Week 0 (Baseline) to Week 14 and 1-week Follow-up Period (Week 15) for SK&F-105517-D"}, {"measure": "Mean Change From Baseline in Albumin and Total Protein at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Creatine Kinase, and Gamma Glutamyl Transferase at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Amylase at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Total Bilirubin, Creatinine, and Uric Acid at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Calcium, Chloride, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Creatine Kinase BB Percentage, Creatine Kinase MB Percentage, and Creatine Kinase MM Percentage at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (BB, brain-derived; MB=cardiac muscle-derived; MM=skeletal muscle-derived.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Each Type of White Blood Cell (WBC) (Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils) at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Hemoglobin and Mean Corpuscular Hemoglobin Concentration at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Hematocrit at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Platelet Count and White Blood Cell Count at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Red Blood Cell Count at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Mean Corpuscular Hemoglobin at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Mean Corpuscular Volume at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Number of Participants With the Indicated Urinalysis Dipstick Results at Baseline and Week 8", "description": "Dipstick test values: Negative (-), Traces (+-), +1, +2, +3. +4. Normal ranges (qualitative): protein, - or +-; glucose, - or +-; occult blood, -; ketones, -.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Heart Rate at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Change From Baseline in Weight at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Number of Participants With the Indicated Electrocardiogram Findings at Baseline and Week 8", "description": "There are 3 categories for electrocardiogram (ECG) findings: normal; abnormal, not clinically significant; and abnormal, clinically significant. Each of the findings was classified by the investigator according to whether it was normal. Abnormal ECGs were further classified according to whether they were felt to be clinically significant in the medical and scientific judgment of the investigator.", "timeFrame": "Baseline and Week 8"}, {"measure": "Cardiothoracic Ratio at Baseline and Week 8", "description": "Cardiothoracic ratio is a marker of the degree of heart enlargement and was measured by chest X-ray. It is shown as the ratio of the transverse diameter of the heart to the transverse diameter of the thorax, and is measured as a percentage.", "timeFrame": "Baseline and Week 8"}], "secondaryOutcomes": [{"measure": "Maximum Plasma Concentration (Cmax) and Trough Plasma Concentration (Cmin) of S-carvedilol, R-carvedilol, and M4 Active Metabolite (SB-203231) at Week 8", "description": "Maximum Plasma Concentration (Cmax) and Trough Plasma Concentration (Cmin) of S-carvedilol, R-carvedilol, and M4 active Metabolite (SB-203231) were measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK\\&F-105517-D group and Groups D, E, and F in the CRV-IR group. The analysis was performed on log-transformed data. Carvedilol is a racemic mixture. Non-selective \u03b2-blocking activity is shown by S-carvedilol, while \u03b11-blocking activity is shown by both S-carvedilol and R-carvedilol.", "timeFrame": "Week 8"}, {"measure": "Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours (AUC0-24) of S-carvedilol, R-carvedilol, and M4 Active Metabolite (SB-203231) at Week 8", "description": "Area under the plasma concentration versus time curve from time zero to 24 hours (AUC0-24) of S-carvedilol, R-carvedilol, and M4 active metabolite (SB-203231) was measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK\\&F-105517-D group and Groups D, E, and F in the CRV-IR group. The analysis was performed on log-transformed data. Carvedilol is a racemic mixture. Non-selective \u03b2-blocking activity is shown by S-carvedilol, while \u03b11-blocking activity is shown by both S-carvedilol and R-carvedilol.", "timeFrame": "Week 8"}, {"measure": "Time of Maximal Plasma Concentration (Tmax) of S-carvedilol, R-carvedilol, and M4 Active Metabolite (SB-203231) at Week 8", "description": "Time of maximal plasma concentration (tmax) of S-carvedilol, R-carvedilol, and M4 active metabolite (SB-203231) was measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK\\&F-105517-D group and Groups D, E, and F in the CRV-IR group. Carvedilol is a racemic mixture. Non-selective \u03b2-blocking activity is shown by S-carvedilol, while \u03b11-blocking activity is shown by both S-carvedilol and R-carvedilol.", "timeFrame": "Week 8"}, {"measure": "Adjusted Mean Change From Baseline in Systolic Blood Pressure at Week 8", "description": "Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Adjusted Mean Change From Baseline in Diastolic Blood Pressure at Week 8", "description": "Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Adjusted Mean Change From Baseline in Mean Heart Rate at Week 8", "description": "Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value.", "timeFrame": "Baseline and Week 8"}, {"measure": "Number of Participants With the Indicated Change From Baseline New York Heart Association (NYHA) Functional Class at Week 8", "description": "The NYHA classification assesses the severity of symptoms of heart failure as judged by the investigator and is comprised of. 4 classes: I, no resulting limitations on physical activity (PA); II, slight limitations on PA; III, marked limitations on PA; IV, inability to carry out any PA without discomfort. The number of participants with any change from Baseline in the NYHA Functional Class at Week 8 was calculated. Improved=class at the visit is decreased compared to baseline class, Unchanged=class at the visit is stable, Worsened=class at the visit is increased compared to baseline class.", "timeFrame": "Baseline and Week 8"}, {"measure": "Mean Plasma Brain Natriuretic Peptide Concentration at Baseline and Week 8", "description": "Brain natriuretic peptide is a surrogate marker of the severity of heart failure and was measured by a central laboratory.", "timeFrame": "Baseline and Week 8"}, {"measure": "Echocardiogram Results: Left Ventricular Ejection Fraction at Baseline and Week 8", "description": "Left ventricular ejection fraction (LVEF) is a marker of left ventricular systolic function and was measured by echocardiogram. It is shown as the ratio of left ventricular stroke volume (LVSV) to left ventricular end-diastolic volume (LVEDV), and is measured as a percentage.", "timeFrame": "Baseline and Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n* Patients with symptomatically stable chronic heart failure (CHF) based on ischemic heart disease or dilated cardiomyopathy\n* Patients who are maintained on basic heart failure therapy with angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blocker (ARB) and their dosage/administration is not changed within 2 weeks\n* Patients diagnosed with New York Heart Association (NYHA) class I to III\n* Patients with a left ventricular ejection fraction (LVEF) between 25% and 45%\n\nExclusion Criteria:\n\n* Patients contraindicated for \u00df-blockers\n* Patients with occurrence of acute myocardial infarction within 2 weeks\n* Patients with unstable angina, coronary spastic angina, or angina at rest\n* Patients who have collected blood \\>400 mL within 4 months prior to screening or \\>200 mL within 1 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Chiba", "zip": "296-8602", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "GSK Investigational Site", "city": "Ehime", "zip": "794-0006", "country": "Japan", "geoPoint": {"lat": 33.63163, "lon": 132.76886}}, {"facility": "GSK Investigational Site", "city": "Hiroshima", "zip": "737-0023", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "GSK Investigational Site", "city": "Hokkaido", "zip": "060-0033", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "GSK Investigational Site", "city": "Hokkaido", "zip": "063-0005", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "GSK Investigational Site", "city": "Kanagawa", "zip": "210-0852", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "GSK Investigational Site", "city": "Kanagawa", "zip": "238-8558", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "GSK Investigational Site", "city": "Mie", "zip": "511-0068", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Nagano", "zip": "397-8555", "country": "Japan", "geoPoint": {"lat": 36.65, "lon": 138.18333}}, {"facility": "GSK Investigational Site", "city": "Nagasaki", "zip": "859-3615", "country": "Japan", "geoPoint": {"lat": 32.75, "lon": 129.88333}}, {"facility": "GSK Investigational Site", "city": "Oita", "zip": "879-5593", "country": "Japan", "geoPoint": {"lat": 33.23333, "lon": 131.6}}, {"facility": "GSK Investigational Site", "city": "Osaka", "zip": "565-8565", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "GSK Investigational Site", "city": "Saga", "zip": "843-0393", "country": "Japan", "geoPoint": {"lat": 33.23333, "lon": 130.3}}, {"facility": "GSK Investigational Site", "city": "Saitama", "zip": "364-8501", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "GSK Investigational Site", "city": "Shizuoka", "zip": "410-2295", "country": "Japan", "geoPoint": {"lat": 34.98333, "lon": 138.38333}}, {"facility": "GSK Investigational Site", "city": "Shizuoka", "zip": "411-8611", "country": "Japan", "geoPoint": {"lat": 34.98333, "lon": 138.38333}}, {"facility": "GSK Investigational Site", "city": "Shizuoka", "zip": "427-8502", "country": "Japan", "geoPoint": {"lat": 34.98333, "lon": 138.38333}}, {"facility": "GSK Investigational Site", "city": "Shizuoka", "zip": "430-8502", "country": "Japan", "geoPoint": {"lat": 34.98333, "lon": 138.38333}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "141-0001", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "142-8666", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "153-8515", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "196-0003", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Wakayama", "zip": "640-8158", "country": "Japan", "geoPoint": {"lat": 34.23333, "lon": 135.16667}}]}, "referencesModule": {"references": [{"pmid": "22240593", "type": "BACKGROUND", "citation": "Kitakaze M, Sarai N, Ando H, Sakamoto T, Nakajima H. Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure. Circ J. 2012;76(3):668-74. doi: 10.1253/circj.cj-11-0210. Epub 2012 Jan 12."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "CRV110734", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "CRV110734", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "CRV110734", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "CRV110734", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "CRV110734", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants randomized to receive SK\\&F-105517-D underwent 2 weeks of observation, 8 weeks of Primary Evaluation, 4 weeks of Exploratory Evaluation, 2 weeks of dose-tapering, and 1 week of Follow-up period. Participants randomized to receive CRV-IR underwent 2 weeks of observation, 8 weeks of Primary Evaluation, and 1 week of Follow-up.", "groups": [{"id": "FG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "FG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "periods": [{"title": "8-Week Primary Evaluation Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Met Protocol-defined Stopping Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}, {"title": "4-Week Exploratory Evaluation Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Met Protocol-defined Stopping Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "BG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "41"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "62.7", "spread": "8.17"}, {"groupId": "BG001", "value": "66.7", "spread": "12.00"}, {"groupId": "BG002", "value": "64.6", "spread": "10.20"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "38"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Asian-Japanese Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "41"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Events by Severity From Week 0 Through Week 8 (CRV-IR) or Week 14 (SK&F-105517-D)", "description": "Drug-related adverse events (AEs) were defined as AEs that were judged to have a relationship with the investigational product by the investigator (or subinvestigator) with the use of clinical judgment and the Clinical Investigator Brochure to determine the relationship. Refer to adverse event information for type and frequency of adverse events.", "populationDescription": "Safety Population: all participants who received at least one dose of the investigational product", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Treatment Period from Week 0 (Baseline) to Week 8 and 1-week Follow-up Period (Week 9) for CRV-IR; Treatment Period from Week 0 (Baseline) to Week 14 and 1-week Follow-up Period (Week 15) for SK&F-105517-D", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}]}]}, {"title": "Mild", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Severe (drug-related)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Moderate (drug-related)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Mild (drug-related)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Maximum Plasma Concentration (Cmax) and Trough Plasma Concentration (Cmin) of S-carvedilol, R-carvedilol, and M4 Active Metabolite (SB-203231) at Week 8", "description": "Maximum Plasma Concentration (Cmax) and Trough Plasma Concentration (Cmin) of S-carvedilol, R-carvedilol, and M4 active Metabolite (SB-203231) were measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK\\&F-105517-D group and Groups D, E, and F in the CRV-IR group. The analysis was performed on log-transformed data. Carvedilol is a racemic mixture. Non-selective \u03b2-blocking activity is shown by S-carvedilol, while \u03b11-blocking activity is shown by both S-carvedilol and R-carvedilol.", "populationDescription": "PK Parameter Population: total of 13 participants, including 3 who gave samples in group F at Week 8 in CRV-IR group; total of 15 participants, including 4 who gave samples at Week 8 in the SK\\&F-105517-D group)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "nanograms per milliliter (ng/mL)", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"title": "S-carvedilol, Cmax", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.7952", "lowerLimit": "5.8993", "upperLimit": "7.8272"}, {"groupId": "OG001", "value": "12.8171", "lowerLimit": "3.6610", "upperLimit": "44.8731"}]}]}, {"title": "S-carvedilol, Cmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.2072", "lowerLimit": "0.1282", "upperLimit": "11.3641"}, {"groupId": "OG001", "value": "3.3796", "lowerLimit": "1.8809", "upperLimit": "6.0727"}]}]}, {"title": "R-carvedilol, Cmax", "categories": [{"measurements": [{"groupId": "OG000", "value": "19.1864", "lowerLimit": "9.3670", "upperLimit": "39.2994"}, {"groupId": "OG001", "value": "27.1306", "lowerLimit": "8.9369", "upperLimit": "82.3626"}]}]}, {"title": "R-carvedilol, Cmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.9445", "lowerLimit": "1.7119", "upperLimit": "5.0647"}, {"groupId": "OG001", "value": "4.2565", "lowerLimit": "2.3297", "upperLimit": "7.7768"}]}]}, {"title": "SB-203231, Cmax", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.1665", "lowerLimit": "2.5819", "upperLimit": "3.8833"}, {"groupId": "OG001", "value": "6.3937", "lowerLimit": "2.3918", "upperLimit": "17.0913"}]}]}, {"title": "SB-203231, Cmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4843", "lowerLimit": "0.2322", "upperLimit": "1.0101"}, {"groupId": "OG001", "value": "1.2386", "lowerLimit": "0.7761", "upperLimit": "1.9769"}]}]}]}, {"type": "SECONDARY", "title": "Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours (AUC0-24) of S-carvedilol, R-carvedilol, and M4 Active Metabolite (SB-203231) at Week 8", "description": "Area under the plasma concentration versus time curve from time zero to 24 hours (AUC0-24) of S-carvedilol, R-carvedilol, and M4 active metabolite (SB-203231) was measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK\\&F-105517-D group and Groups D, E, and F in the CRV-IR group. The analysis was performed on log-transformed data. Carvedilol is a racemic mixture. Non-selective \u03b2-blocking activity is shown by S-carvedilol, while \u03b11-blocking activity is shown by both S-carvedilol and R-carvedilol.", "populationDescription": "Pharmacokinetic (PK) Parameter Population: all participants who received the study drug at each dose level and provided sufficient PK concentration data and the data for estimation of PK parameters (total of 13 participants, 3 gave samples at Week 8 in CRV-IR group; total of 15 participants, 4 gave samples at Week 8 in the SK\\&F-105517-D group)", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "hours * nanograms per milliliter (ng/mL)", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"title": "S-carvedilol", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.040", "lowerLimit": "12.856", "upperLimit": "280.396"}, {"groupId": "OG001", "value": "155.109", "lowerLimit": "63.319", "upperLimit": "379.959"}]}]}, {"title": "R-carvedilol", "categories": [{"measurements": [{"groupId": "OG000", "value": "170.728", "lowerLimit": "131.607", "upperLimit": "221.478"}, {"groupId": "OG001", "value": "284.313", "lowerLimit": "132.307", "upperLimit": "610.954"}]}]}, {"title": "SB-203231", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.113", "lowerLimit": "14.853", "upperLimit": "53.209"}, {"groupId": "OG001", "value": "64.687", "lowerLimit": "28.012", "upperLimit": "149.382"}]}]}]}, {"type": "SECONDARY", "title": "Time of Maximal Plasma Concentration (Tmax) of S-carvedilol, R-carvedilol, and M4 Active Metabolite (SB-203231) at Week 8", "description": "Time of maximal plasma concentration (tmax) of S-carvedilol, R-carvedilol, and M4 active metabolite (SB-203231) was measured. Participants in each treatment group were divided into 3 groups by pharmacokinetic sampling timing: Groups A, B, and C in the SK\\&F-105517-D group and Groups D, E, and F in the CRV-IR group. Carvedilol is a racemic mixture. Non-selective \u03b2-blocking activity is shown by S-carvedilol, while \u03b11-blocking activity is shown by both S-carvedilol and R-carvedilol.", "populationDescription": "PK Parameter Population: total of 13 participants, including 3 in group F who gave samples at Week 8 in the CRV-IR group; total of 15 participants, including 4 in group C who gave samples at Week 8 in the SK\\&F-105517-D group", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"title": "S-carvedilol", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.983", "lowerLimit": "1.00", "upperLimit": "2.03"}, {"groupId": "OG001", "value": "5.958", "lowerLimit": "4.00", "upperLimit": "6.08"}]}]}, {"title": "R-carvedilol", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.983", "lowerLimit": "1.00", "upperLimit": "2.03"}, {"groupId": "OG001", "value": "5.958", "lowerLimit": "4.00", "upperLimit": "6.08"}]}]}, {"title": "SB-203231", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.983", "lowerLimit": "1.00", "upperLimit": "2.03"}, {"groupId": "OG001", "value": "5.958", "lowerLimit": "4.00", "upperLimit": "6.08"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Systolic Blood Pressure at Week 8", "description": "Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value.", "populationDescription": "Pharmacodynamic (PD) Population: all participants measurable at the PD endpoints (18 participants at baseline and 3 participants at Week 8 in CRV-IR group, 19 participants at baseline and 4 participants at Week 8 in SK\\&F-105517-D group)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "millimeters of mercury (mmHg)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "24 h", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.84", "spread": "4.119"}, {"groupId": "OG001", "value": "-1.45", "spread": "3.567"}]}]}, {"title": "Morning", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.34", "spread": "4.412"}, {"groupId": "OG001", "value": "-4.78", "spread": "3.819"}]}]}, {"title": "Afternoon", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.14", "spread": "2.734"}, {"groupId": "OG001", "value": "-12.06", "spread": "2.361"}]}]}, {"title": "Night", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.04", "spread": "4.786"}, {"groupId": "OG001", "value": "5.17", "spread": "4.139"}]}]}, {"title": "Waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.39", "spread": "2.857"}, {"groupId": "OG001", "value": "-9.99", "spread": "2.472"}]}]}, {"title": "Sleeping", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.85", "spread": "3.223"}, {"groupId": "OG001", "value": "13.20", "spread": "2.787"}]}]}, {"title": "PDmax", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.74", "spread": "7.772"}, {"groupId": "OG001", "value": "-10.19", "spread": "6.656"}]}]}, {"title": "PDmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.89", "spread": "5.416"}, {"groupId": "OG001", "value": "1.42", "spread": "4.685"}]}]}, {"title": "PDmax/PDmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.103"}, {"groupId": "OG001", "value": "-0.17", "spread": "0.088"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "9.38", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.75", "ciUpperLimit": "24.51", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.449", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the 24 h assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Median Difference (Net)", "paramValue": "7.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.68", "ciUpperLimit": "23.79", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.849", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Morning assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-1.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.04", "ciUpperLimit": "8.20", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.645", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Afternoon assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "14.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.45", "ciUpperLimit": "31.87", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.361", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Night assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "0.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.12", "ciUpperLimit": "10.92", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.790", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Waking assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "25.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "13.16", "ciUpperLimit": "36.93", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.281", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Sleeping assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-0.45", "ciPctValue": "95", "ciLowerLimit": "-29.94", "ciUpperLimit": "29.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "10.62", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmax assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "8.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.67", "ciUpperLimit": "28.28", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.194", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmin assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.63", "ciUpperLimit": "0.15", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.142", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmax/PDmin assessment."}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Albumin and Total Protein at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "grams per liter (g/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Albumin", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.7", "spread": "2.87"}, {"groupId": "OG001", "value": "-1.9", "spread": "2.90"}]}]}, {"title": "Total Protein", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "4.27"}, {"groupId": "OG001", "value": "-1.6", "spread": "4.72"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Creatine Kinase, and Gamma Glutamyl Transferase at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "international units per liter (IU/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Alkaline Phosphatase", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.9", "spread": "18.45"}, {"groupId": "OG001", "value": "-5.0", "spread": "21.13"}]}]}, {"title": "Alanine Aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "6.48"}, {"groupId": "OG001", "value": "3.8", "spread": "9.39"}]}]}, {"title": "Aspartate Aminotransferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "3.87"}, {"groupId": "OG001", "value": "1.4", "spread": "7.19"}]}]}, {"title": "Creatine Kinase", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.4", "spread": "55.58"}, {"groupId": "OG001", "value": "-0.1", "spread": "65.54"}]}]}, {"title": "Gamma Glutamyl Transferase", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "3.68"}, {"groupId": "OG001", "value": "2.4", "spread": "10.62"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Amylase at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units per liter (U/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.2", "spread": "9.98"}, {"groupId": "OG001", "value": "-0.1", "spread": "15.66"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Total Bilirubin, Creatinine, and Uric Acid at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "micromoles per liter (umol/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Total Bilirubin", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.555", "spread": "2.3514"}, {"groupId": "OG001", "value": "-4.489", "spread": "3.8712"}]}]}, {"title": "Creatinine", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.5451", "spread": "14.97638"}, {"groupId": "OG001", "value": "-4.5305", "spread": "5.85307"}]}]}, {"title": "Uric Acid", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.8215", "spread": "48.16177"}, {"groupId": "OG001", "value": "14.1265", "spread": "80.67868"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Calcium, Chloride, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimoles per liter (mmol/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Calcium", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.027218", "spread": "0.1364081"}, {"groupId": "OG001", "value": "-0.056138", "spread": "0.0592680"}]}]}, {"title": "Chloride", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "1.60"}, {"groupId": "OG001", "value": "2.4", "spread": "2.20"}]}]}, {"title": "Glucose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.136252", "spread": "2.9159783"}, {"groupId": "OG001", "value": "-1.956728", "spread": "2.8733368"}]}]}, {"title": "Potassium", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.361"}, {"groupId": "OG001", "value": "0.07", "spread": "0.474"}]}]}, {"title": "Sodium", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "2.30"}, {"groupId": "OG001", "value": "1.6", "spread": "1.41"}]}]}, {"title": "Urea/Blood Urea Nitrogen", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.61339", "spread": "2.523049"}, {"groupId": "OG001", "value": "-0.58013", "spread": "1.023316"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Creatine Kinase BB Percentage, Creatine Kinase MB Percentage, and Creatine Kinase MM Percentage at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value. (BB, brain-derived; MB=cardiac muscle-derived; MM=skeletal muscle-derived.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of Total Creatine Kinase", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Creatine Kinase BB percentage", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "0.60"}, {"groupId": "OG001", "value": "0.5", "spread": "0.93"}]}]}, {"title": "Creatine Kinase MB percentage", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "0.65"}, {"groupId": "OG001", "value": "-0.1", "spread": "0.83"}]}]}, {"title": "Creatine Kinase MM percentage", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "1.30"}, {"groupId": "OG001", "value": "0.8", "spread": "1.75"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Each Type of White Blood Cell (WBC) (Basophils, Eosinophils, Lymphocytes, Monocytes, and Total Neutrophils) at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of each WBC type in WBC count", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Basophils", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.403"}, {"groupId": "OG001", "value": "-0.06", "spread": "0.325"}]}]}, {"title": "Eosinophils", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "1.547"}, {"groupId": "OG001", "value": "0.76", "spread": "1.412"}]}]}, {"title": "Lymphocytes", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "6.052"}, {"groupId": "OG001", "value": "2.21", "spread": "9.174"}]}]}, {"title": "Monocytes", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "1.358"}, {"groupId": "OG001", "value": "1.28", "spread": "1.356"}]}]}, {"title": "Total Neutrophils", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "7.875"}, {"groupId": "OG001", "value": "-4.31", "spread": "11.180"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Hemoglobin and Mean Corpuscular Hemoglobin Concentration at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "grams per liter (g/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Hemoglobin", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.3", "spread": "8.05"}, {"groupId": "OG001", "value": "-3.9", "spread": "8.04"}]}]}, {"title": "Mean Corpuscular Hemoglobin Concentration", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3", "spread": "4.90"}, {"groupId": "OG001", "value": "-1.9", "spread": "6.01"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Hematocrit at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "proportion of 1 (SI)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.0085", "spread": "0.02306"}, {"groupId": "OG001", "value": "-0.0095", "spread": "0.02287"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Platelet Count and White Blood Cell Count at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "gibi (2 to the power of 30)/liter (Gi/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Platelet Count", "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.9", "spread": "23.28"}, {"groupId": "OG001", "value": "-11.1", "spread": "14.54"}]}]}, {"title": "White Blood Cell Count", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.297", "spread": "0.9850"}, {"groupId": "OG001", "value": "-0.498", "spread": "1.9516"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Red Blood Cell Count at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "tebi (2 to the power of 40)/liter (Ti/L)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.091", "spread": "0.2390"}, {"groupId": "OG001", "value": "-0.087", "spread": "0.2295"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Mean Corpuscular Hemoglobin at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "picograms (pg)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.515"}, {"groupId": "OG001", "value": "-0.21", "spread": "0.372"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Mean Corpuscular Volume at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "femtoliters (fL)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "1.38"}, {"groupId": "OG001", "value": "-0.1", "spread": "1.96"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With the Indicated Urinalysis Dipstick Results at Baseline and Week 8", "description": "Dipstick test values: Negative (-), Traces (+-), +1, +2, +3. +4. Normal ranges (qualitative): protein, - or +-; glucose, - or +-; occult blood, -; ketones, -.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Urine Glucose, Negative, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Urine Glucose, Traces, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 1+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 2+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 3+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 4+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, Negative, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Urine Ketones, Traces, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 1+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 2+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 3+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 4+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Occult Blood, Negative, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}]}]}, {"title": "Urine Occult Blood, Traces, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Urine Occult Blood, 1+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Urine Occult Blood, 2+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Urine Occult Blood, 3+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Occult Blood, 4+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, Negative, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": "Urine Protein, Traces, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, 1+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Urine Protein, 2+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, 3+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, 4+, Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, Negative, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Urine Glucose, Traces, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 1+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 2+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 3+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Glucose, 4+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, Negative, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Urine Ketones, Traces, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 1+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 2+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 3+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Ketones, 4+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Occult Blood, Negative, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Urine Occult Blood, Traces, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Occult Blood, 1+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Occult Blood, 2+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Occult Blood, 3+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Occult Blood, 4+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, Negative, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Urine Protein, Traces, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein 1+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, 2+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, 3+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Urine Protein, 4+, Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeters of mercury (mmHg)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Systolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.7", "spread": "20.68"}, {"groupId": "OG001", "value": "10.0", "spread": "15.28"}]}]}, {"title": "Diastolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "11.69"}, {"groupId": "OG001", "value": "2.8", "spread": "5.68"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Heart Rate at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats per minute", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.4", "spread": "10.54"}, {"groupId": "OG001", "value": "-10.6", "spread": "18.87"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Weight at Week 8", "description": "Mean change from baseline was calculated as the Week 8 value minus the Baseline value.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kilograms (kg)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.29", "spread": "1.490"}, {"groupId": "OG001", "value": "-0.11", "spread": "2.303"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With the Indicated Electrocardiogram Findings at Baseline and Week 8", "description": "There are 3 categories for electrocardiogram (ECG) findings: normal; abnormal, not clinically significant; and abnormal, clinically significant. Each of the findings was classified by the investigator according to whether it was normal. Abnormal ECGs were further classified according to whether they were felt to be clinically significant in the medical and scientific judgment of the investigator.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Normal, Baseline (BL), n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Abnormal-Not clinically significant, BL, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Abnormal-Clinically significant, BL, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "9"}]}]}, {"title": "Normal, Week (W) 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Abnormal-Not clinically significant, W8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Abnormal-Clinically significant, W8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "PRIMARY", "title": "Cardiothoracic Ratio at Baseline and Week 8", "description": "Cardiothoracic ratio is a marker of the degree of heart enlargement and was measured by chest X-ray. It is shown as the ratio of the transverse diameter of the heart to the transverse diameter of the thorax, and is measured as a percentage.", "populationDescription": "Safety Population: 22 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Baseline, n=22, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.70", "spread": "4.536"}, {"groupId": "OG001", "value": "53.58", "spread": "8.098"}]}]}, {"title": "Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.91", "spread": "4.309"}, {"groupId": "OG001", "value": "52.35", "spread": "7.545"}]}]}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Diastolic Blood Pressure at Week 8", "description": "Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value.", "populationDescription": "Pharmacodynamic (PD) Population: all participants measurable at the PD endpoints (18 participants at baseline and 3 participants at Week 8 in CRV-IR group, 19 participants at baseline and 4 participants at Week 8 in SK\\&F-105517-D group)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "millimeters of mercury (mmHg)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "24 h", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.10", "spread": "3.387"}, {"groupId": "OG001", "value": "-4.89", "spread": "2.852"}]}]}, {"title": "Morning", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.68", "spread": "4.449"}, {"groupId": "OG001", "value": "-8.24", "spread": "3.766"}]}]}, {"title": "Afternoon", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.32", "spread": "2.760"}, {"groupId": "OG001", "value": "-10.25", "spread": "2.336"}]}]}, {"title": "Night", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.01", "spread": "4.190"}, {"groupId": "OG001", "value": "0.73", "spread": "3.506"}]}]}, {"title": "Waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.11", "spread": "2.902"}, {"groupId": "OG001", "value": "-8.56", "spread": "2.458"}]}]}, {"title": "Sleeping", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.68", "spread": "1.197"}, {"groupId": "OG001", "value": "5.38", "spread": "1.011"}]}]}, {"title": "PDmax", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.45", "spread": "6.702"}, {"groupId": "OG001", "value": "-17.91", "spread": "5.796"}]}]}, {"title": "PDmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.34", "spread": "3.852"}, {"groupId": "OG001", "value": "-0.24", "spread": "3.291"}]}]}, {"title": "PDmax/PDmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.24", "spread": "0.111"}, {"groupId": "OG001", "value": "-0.36", "spread": "0.094"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "2.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.20", "ciUpperLimit": "15.63", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.833", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the 24 h assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-0.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-17.95", "ciUpperLimit": "16.84", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.265", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Morning assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-4.93", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.71", "ciUpperLimit": "5.86", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.885", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Afternoon assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "9.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.11", "ciUpperLimit": "26.59", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.070", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Night assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-3.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.78", "ciUpperLimit": "7.88", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.080", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Waking assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "18.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "13.36", "ciUpperLimit": "22.76", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.694", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Sleeping assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-7.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.17", "ciUpperLimit": "17.26", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "8.902", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmax assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "1.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.61", "ciUpperLimit": "15.80", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.297", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmin assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.54", "ciUpperLimit": "0.30", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.152", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmax/PDmin assessment."}]}, {"type": "SECONDARY", "title": "Adjusted Mean Change From Baseline in Mean Heart Rate at Week 8", "description": "Pharmacodynamic (PD) assessment points were 24 hours (h) (from time of first reading to time of last reading), morning (6 am-12 pm), afternoon (12-6 pm), night (6 pm-6 am on following day), waking (8 am-9 pm), sleeping (0-5 am), PDmax (maximal value obtained with each participant during the 0-24 h interval), PDmin (minimal value obtained with each participant during the 0-24 h interval), and PDmax/PDmin. PDmax/PDmim was calculated as the ratio of the PDmax to PDmin, and it showed the degree of change during the 0-24 h interval. The mean was adjusted for Baseline value.", "populationDescription": "PD Population: all participants measurable at the PD endpoints (18 participants at baseline and 3 participants at Week 8 in CRV-IR group, 19 participants at baseline and 4 participants at Week 8 in SK\\&F-105517-D group)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "beats per minute", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "24 h", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.38", "spread": "2.385"}, {"groupId": "OG001", "value": "-15.37", "spread": "2.058"}]}]}, {"title": "Morning", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.59", "spread": "2.225"}, {"groupId": "OG001", "value": "-14.87", "spread": "1.923"}]}]}, {"title": "Afternoon", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.96", "spread": "2.345"}, {"groupId": "OG001", "value": "-15.93", "spread": "2.006"}]}]}, {"title": "Night", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.12", "spread": "2.760"}, {"groupId": "OG001", "value": "-15.26", "spread": "2.387"}]}]}, {"title": "Waking", "categories": [{"measurements": [{"groupId": "OG000", "value": "-12.53", "spread": "2.250"}, {"groupId": "OG001", "value": "-15.53", "spread": "1.933"}]}]}, {"title": "Sleeping", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.16", "spread": "3.536"}, {"groupId": "OG001", "value": "-14.28", "spread": "3.060"}]}]}, {"title": "PDmax", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.43", "spread": "2.758"}, {"groupId": "OG001", "value": "-23.43", "spread": "2.366"}]}]}, {"title": "PDmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.04", "spread": "3.830"}, {"groupId": "OG001", "value": "-3.47", "spread": "3.276"}]}]}, {"title": "PDmax/PDmin", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.93", "spread": "0.095"}, {"groupId": "OG001", "value": "-1.27", "spread": "0.080"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-3.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.84", "ciUpperLimit": "4.86", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.187", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the 24 h assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-5.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.50", "ciUpperLimit": "2.95", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.962", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Morning assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-1.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.89", "ciUpperLimit": "6.94", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.209", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Afternoon assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-4.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.32", "ciUpperLimit": "6.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.665", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Night assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-2.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.45", "ciUpperLimit": "5.47", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.047", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Waking assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-3.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.12", "ciUpperLimit": "9.89", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.686", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the Sleeping assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-10.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.41", "ciUpperLimit": "0.41", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "3.749", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmax assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-1.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.00", "ciUpperLimit": "13.15", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5.249", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmin assessment."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Mean Difference (Net)", "paramValue": "-0.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.71", "ciUpperLimit": "0.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.133", "estimateComment": "The mean treatment difference is calculated as SK\\&F-105517-D minus CRV-IR for the PDmax/PDmin assessment."}]}, {"type": "SECONDARY", "title": "Number of Participants With the Indicated Change From Baseline New York Heart Association (NYHA) Functional Class at Week 8", "description": "The NYHA classification assesses the severity of symptoms of heart failure as judged by the investigator and is comprised of. 4 classes: I, no resulting limitations on physical activity (PA); II, slight limitations on PA; III, marked limitations on PA; IV, inability to carry out any PA without discomfort. The number of participants with any change from Baseline in the NYHA Functional Class at Week 8 was calculated. Improved=class at the visit is decreased compared to baseline class, Unchanged=class at the visit is stable, Worsened=class at the visit is increased compared to baseline class.", "populationDescription": "Efficacy Population: all participants measurable at the efficacy endpoints (20 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group. Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Unchanged", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "Worse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Mean Plasma Brain Natriuretic Peptide Concentration at Baseline and Week 8", "description": "Brain natriuretic peptide is a surrogate marker of the severity of heart failure and was measured by a central laboratory.", "populationDescription": "Efficacy Population: all participants measurable at the efficacy endpoints (20 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group). Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L (nanogram per Liter)", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Baseline, n=20, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "108.93", "spread": "112.192"}, {"groupId": "OG001", "value": "226.46", "spread": "339.640"}]}]}, {"title": "Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "64.88", "spread": "62.020"}, {"groupId": "OG001", "value": "111.93", "spread": "84.298"}]}]}]}, {"type": "SECONDARY", "title": "Echocardiogram Results: Left Ventricular Ejection Fraction at Baseline and Week 8", "description": "Left ventricular ejection fraction (LVEF) is a marker of left ventricular systolic function and was measured by echocardiogram. It is shown as the ratio of left ventricular stroke volume (LVSV) to left ventricular end-diastolic volume (LVEDV), and is measured as a percentage.", "populationDescription": "Efficacy Population: all participants measurable at the efficacy endpoints (20 participants at baseline and 11 participants at Week 8 in the CRV-IR group; 19 participants at baseline and 8 participants at Week 8 in the SK\\&F-105517-D group). Some participants in each treatment arm withdrew prematurely.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose."}, {"id": "OG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"title": "Baseline, n=20, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "34.0", "spread": "8.43"}, {"groupId": "OG001", "value": "32.2", "spread": "10.09"}]}]}, {"title": "Week 8, n=11, 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "42.0", "spread": "13.36"}, {"groupId": "OG001", "value": "37.6", "spread": "10.14"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Treatment Period from Week 0 (Baseline) to Week 8 and 1-week Follow-up Period (Week 9) for CRV-IR; Treatment Period from Week 0 (Baseline) to Week 14 and 1-week Follow-up Period (Week 15) for SK&F-105517-D.", "eventGroups": [{"id": "EG000", "title": "CRV-IR", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received an initial dose of an immediate-release (IR) formulation of carvedilol (CRV) as a 1.25 milligram (mg) tablet twice daily (BID) (2.5 mg/day) at Week 0, followed by an increased dose of CRV-IR 2.5 mg tablet BID (5 mg/day) at Week 1. The dose was then increased to 5 mg BID (10 mg/day) at Week 4, and finally to 10 mg BID (20 mg/day) at Week 6. The participants on CRV-IR were switched to the marketed CRV-IR in Week 1 of the Follow-up Period; the investigator or subinvestigator determined the dose of the marketed CRV-IR based on the last dose administered during the Primary Evaluation Period after confirming the safety and tolerability of the dose.", "seriousNumAffected": 1, "seriousNumAtRisk": 22, "otherNumAffected": 11, "otherNumAtRisk": 22}, {"id": "EG001", "title": "SK&F-105517-D", "description": "In the 8-week Primary Evaluation Period (including the 2-week Run-in Period \\[from Week 0 as Baseline\\]), participants received a CRV-IR 1.25 mg and 2.5 mg tablet BID at Weeks 0 and 1, respectively. They then received a 10 mg extended-release capsule of carvedilol (SK\\&F-105517-D) once daily (OD) at Week 2; the dose was then increased to 20 mg OD and finally to 40 mg OD at 2-week intervals. The dose was increased from 40 mg to 60 mg and finally to 80 mg at 2-week intervals in the 4-week Exploratory Evaluation Period after confirming that each dose was well tolerated without safety concern and that the participant met all of the dose-escalation criteria. During the 2-week Dose-tapering Period set up to prepare for switch to the marketed CRV-IR, the dose of SK\\&F-105517-D was reduced to 60 mg OD and then to 40 mg OD at weekly intervals; SK\\&F-105517-D was then switched to the marketed CRV-IR 10 mg tablet BID in the 1-week Follow-up Period.", "seriousNumAffected": 3, "seriousNumAtRisk": 19, "otherNumAffected": 15, "otherNumAtRisk": 19}], "seriousEvents": [{"term": "Bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Blood uric acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Brain natriuretic peptide increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 19}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Blood alkaline phosphatase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Blood calcium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Blood creatine phosphokinase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Cheilitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Dental caries", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Dysgeusia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Gamma-glutamyltransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Glossitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Intracardiac thrombus", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Nodal rhythm", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Platelet count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Skin exfoliation", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 19}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (12.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 22}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 19}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077261", "term": "Carvedilol"}], "ancestors": [{"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058668", "term": "Adrenergic alpha-1 Receptor Antagonists"}, {"id": "D000000317", "term": "Adrenergic alpha-Antagonists"}], "browseLeaves": [{"id": "M1718", "name": "Carvedilol", "asFound": "Circulating", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29194", "name": "Adrenergic alpha-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3669", "name": "Adrenergic alpha-Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}